In this article
- Phase III GC101 Gene Therapy Trial for SMA Type 2: Overview and Objectives ClinicalTrials.gov Identifier
- Study Design, Intervention Arms, and Outcome Measures of the Phase III GC101 SMA Trial
- Eligibility Criteria and Participating Locations for the Phase III GC101 SMA Type 2 Trial in China
- Why GC101 Matters for SMA Type 2 and How to Join the Trial
- How CancerFax Helps
Study Design:
Type: Interventional (Phase III)
Model: Randomized, parallel-assignment
Masking: None (Open-label)
Control: Standard-of-care with nusinersen
Enrollment: 50 participants (estimated)
Intervention Arms:
GC101 Arm (Experimental):
Single intrathecal injection of GC101 (1.2×10¹⁴ vg per patient)
Discontinue prior nusinersen treatment
Control Arm:
Continue standard-of-care nusinersen treatment
Primary Endpoint:
Change in HFMSE (Hammersmith Functional Motor Scale Expanded) score at 52 weeks
Secondary Endpoints:
HFMSE score change at 26 weeks
% of participants with ≥3-point increase in HFMSE
WHO-MGRS milestone achievements (sitting, walking, crawling)
RULM (upper limb motor) and SMAIS (independence) scores at 26 & 52 weeks
Incidence of adverse events (AEs, SAEs, AESIs)
Inclusion Criteria:
Age 2–12 years, with genetically confirmed Type 2 5q-SMA
Received nusinersen for >1 year
No risdiplam within 2 months before screening
Can sit independently but not walk
HFMSE score ≥10
Informed consent from patient/legal guardian
Exclusion Criteria:
Anti-AAV9 antibody titer >1:50
Recent nusinersen (<2 months)
Comorbidities like epilepsy, cerebrospinal fluid disorders, severe scoliosis
Positive for HIV, HCV, HBV, or syphilis
Severe hepatic impairment (ALT/AST ≥3x ULN)
Contraindications to lumbar puncture or glucocorticoids
Gene therapy or other trial participation within 3 months
Participating Locations in China:
The Seventh Medical Center of PLA General Hospital, Beijing
Peking University First Hospital, Beijing
Beijing Children's Hospital
National Children's Medical Center, Shanghai
Shenzhen Children's Hospital
Children's Hospital of Soochow University, Suzhou
Wuhan Children's Hospital, Wuhan
GC101 aims to replace the missing SMN1 gene in Type 2 SMA patients with a single-dose intrathecal injection. This study could redefine treatment by offering a long-lasting, potentially one-time therapy alternative to ongoing maintenance drugs like nusinersen.
CancerFax helps patients explore participation in advanced gene therapy clinical trials worldwide.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.